AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The transcription factor CCAAT/enhancer binding protein alpha, or C/EBPalpha, encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold lower CEBPA RNA levels and undetectable C/EBPalpha protein levels compared with other subgroups of AML patients. Conditional expression of RUNX1-CBF2T1 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBPalpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBPalpha in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBPalpha expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and abolishes C/EBP 𝛂 expression. 54”
From RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. (2003) · cites this paper as [54]
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“The U937T cell line in which U937 cells were stably transfected with the tetracycline transactivator (tTA) under the control of a tetracycline responsive elemen”
BackgroundEstablishment and characterization of a human histiocytic lymphoma cell line (U‐937)
Sundström, C., & Nilsson, K. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910170504 · Cited by 2,407
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Luciferase reporter gene vectors for analysis of promoters and enhancers.
Nordeen, S. K. (1988) · PubMed · Cited by 994
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Self-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901 · cited 1×
“a the abnormalities were one del (9)(q22;q34); one t(6;9); one t(10;21)(p11;q22); one 8;one 14; and one complex aberrant karyotype.”
BackgroundSelf-citationMiyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Cited by
Items 101–200 of 462
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Goldman, S. L., Hassan, C., Khunte, M., Soldatenko, A., Jong, Y., Afshinnekoo, E., & Mason, C. E. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00133 · Cited by 101
Behre, G., Singh, S. M., Liu, H., Bortolin, L. T., Christopeit, M., Radomska, H. S., Rangatia, J., Hiddemann, W., Friedman, A. D., & Tenen, D. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202301200 · Cited by 84
“(Pabst et al., 2001a) Furthermore, AML1-ETO associates with C/EBPα, inhibits C/EBPα dependent transcription of myeloid cell specific rat defensin NP-3 promoter, and blocks granulocytic differentiation.”
BackgroundSelf-citationDunne, J., Cullmann, C., Ritter, M., Martinez-Soria, N., Drescher, B., Debernardi, S., Skoulakis, S., Hartmann, O., Krause, M., Krauter, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209638 · Cited by 94
“Furthermore, transcript levels of the indirect target gene C/EBPa were also raised twofold (Figure 1c) (Westendorf et al., 1998; Pabst et al., 2001).”
BackgroundZebrafish a genetic model for vertebrate organogenesis and human disorders
Paw, B. H. (2003) · Frontiers in bioscience · doi:10.2741/1092 · Cited by 100
“profiles and contributing to a transformed state (188-192).”
BackgroundAn autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation
Avellino, R., Havermans, M., Erpelinck, C., Sanders, M. A., Hoogenboezem, R., van de Werken, H. J. G., Rombouts, E., van Lom, K., van Strien, P. M. H., Gebhard, C., et al. (2016) · Blood · doi:10.1182/blood-2016-01-695759 · Cited by 83
“Patients with a chromosomal translocation t(8;21)presentwith lowCEBPA expression levels.(14)The t (8;21) generates the AML1-ETO (ie, the RUNX1-RUNX1T1 fusion transcript) fusion protein that binds to sites that are usually bound by RUNX1.”
BackgroundZamanian, M., Veerakumarasivam, A., Abdullah, S., & Rosli, R. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-012-9600-2 · Cited by 86
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
Larizza, L., Magnani, I., & Beghini, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400007565 · Cited by 91
The molecular pathogenesis of acute myeloid leukemia
Steffen, B., Müller‐Tidow, C., Schwäble, J., Berdel, W. E., & Serve, H. L. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.10.012 · Cited by 111
Jiang, Y., Xue, Z.-H., Shen, W.-Z., Du, K.-M., Yan, H.-M., Yu, Y., Peng, Z.-G., Song, M.-G., Tong, J.-H., Chen, Z., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403734 · Cited by 87
NUP98 Dysregulation in Myeloid Leukemogenesis
Moore, M. A. S., Chung, K. Y., Plasilova, M. L., Schuringa, J. J., SHIEH, J. ‐., Zhou, P., & Morrone, G. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1392.019 · Cited by 92
Induction of granulocytic differentiation by 2 pathways
Zhang, P., Nelson, E., Radomska, H. S., Iwasaki-Arai, J., Akashi, K., Friedman, A. D., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v99.12.4406 · Cited by 78
Self-citationCOP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1
Yoshida, A., Kato, J., Nakamae, I., & Yoneda‐Kato, N. (2013) · Blood · doi:10.1182/blood-2012-12-476101 · Cited by 86
Geletu, M., Balkhi, M. Y., Zada, A. A. P., Christopeit, M., Pulikkan, J. A., Trivedi, A. K., Tenen, D. G., & Behre, G. (2007) · Blood · doi:10.1182/blood-2007-01-071035 · Cited by 88
Self-citationAsou, N. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00003-3 · Cited by 80
Feng, J., Iwama, A., Satake, M., & Kohu, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07632.x · Cited by 79
“In particular, RUNX1-chimaeras inhibit the function/expression of CCAAT/enhancer binding protein alpha (C/EBPalpha), a key transcription factor for myeloid differentiation (Pabst et al, 2001; Tokita et al, 2007).”
BackgroundTwist-2 Controls Myeloid Lineage Development and Function
Sharabi, A. B., Aldrich, M., Sosic, D., Olson, E. N., Friedman, A. D., Lee, S.-H., & Chen, S.-Y. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060316 · Cited by 74
“Runx1 and an inhibitor of the C/EBPa promoter [15,16],”
BackgroundHollink, I. H. I. M., van den Heuvel‐Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Zimmermann, M., Peeters, J. K., Valk, P. J. M., Balgobind, B. V., Sonneveld, E., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031336 · Cited by 86
Gorin, N. C., Labopin, M., Frassoni, F., Milpied, N. J., Attal, M., Blaise, D., Meloni, G., Iori, A. P., Michallet, M., Willemze, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3106 · Cited by 73
C/EBPα deregulation as a paradigm for leukemogenesis
Pulikkan, J. A., Tenen, D. G., & Behre, G. (2017) · Leukemia · doi:10.1038/leu.2017.229 · Cited by 79
Self-citationRole of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
Self-citationThe multifaceted functions of C/EBPα in normal and malignant haematopoiesis
Ohlsson, E., Schuster, M. B., Hasemann, M. S., & Porse, B. T. (2015) · Leukemia · doi:10.1038/leu.2015.324 · Cited by 92
Bassères, D. S. D. S., Levantini, E., Ji, H., Monti, S., Elf, S., Dayaram, T., Fenyus, M. L., Kocher, O. N., Golub, T. R., Wong, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1109-1123.2006 · Cited by 73
Self-citationLeong, S. M., Tan, B. X., Ahmad, B., Yan, T., Chee, L. Y., Ang, S. T., Tay, K.-G., Koh, L. P., Yeoh, A. E. J., Koay, E. S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-12-256149 · Cited by 68
Complexity of miR-223 regulation by CEBPA in human AML
Eyholzer, M., Schmid, S., Schardt, J., Haefliger, S., Mueller, B. U., & Pabst, T. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.11.019 · Cited by 77
Self-citationHistone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein
Yang, G., Thompson, M. A., Brandt, S. J., & Hiebert, S. W. (2006) · Oncogene · doi:10.1038/sj.onc.1209760 · Cited by 69
“RUNX1-ETO acts to repress the transcription of key regulatory genes, including transcription factors that regulate cell cycle control and myeloid differentiation such as C/EBPa (Pabst et al., 2001).”
BackgroundMandoli, A., Singh, A. A., Prange, K. H. M., Tijchon, E. J. H., Oerlemans, M. M. P., Dirks, R. A. M., ter Huurne, M., Wierenga, A. T. J., Janssen‐Megens, E. M., Berentsen, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.082 · Cited by 69
“Using an iPSCsmodel system, we verified that overexpression of AML1-ETO induces cell death, suggesting that only a specific dose of AML1-ETO relates to leukemogenesis, corroborating previous findings (Pabst et al., 2001; Tonks et al., 2004).”
ResultMolecular pathogenesis of core binding factor leukemia: current knowledge and future prospects
Goyama, S., & Mulloy, J. C. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0858-z · Cited by 84
“CEBPA is an essential gene for granulopoiesis, and AML1-ETO represses CEBPA expression and its DNA binding activity [24].”
BackgroundComplementing mutations in core binding factor leukemias: from mouse models to clinical applications
Müller, A. M. S., Duque‐Afonso, J., Shizuru, J. A., & Lübbert, M. (2008) · Oncogene · doi:10.1038/onc.2008.196 · Cited by 80
“…of genes that are critical for the establishment and development of normal hematopoiesis, such as interleukin-3 (Cameron et al., 1994), granulocytic differentiation factor C/EBPa (Pabst et al., 2001), MCSF receptor (Zhang et al., 1996) and myeloperoxidase (Nuchprayoon et al., 1994).”
BackgroundKuchenbauer, F. C., Schnittger, S., Look, T., Gilliland, G. D., Tenen, D. G., Haferlach, T., Hiddemann, W., Buske, C., & Schoch, C. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06229.x · Cited by 64
“%) of the total group, whereas no MLL-PTD, CEBPA and KRAS mutations could be found in the investigated samples (Table II).”
BackgroundInfluentialSelf-citationLinkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3
Argiropoulos, B., Palmqvist, L., Yung, E., Kuchenbauer, F. C., Heuser, M., Sly, L. M., Wan, A., Krystal, G., & Humphries, R. K. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.02.011 · Cited by 70
Zardo, G., Cimino, G. G., & Nervi, C. (2008) · Leukemia · doi:10.1038/leu.2008.141 · Cited by 75
Rangatia, J., Vangala, R. K., Treiber, N., Zhang, P., Radomska, H., Tenen, D. G., Hiddemann, W., & Behre, G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8681-8694.2002 · Cited by 62
Self-citationRangatia, J., Vangala, R. K., Singh, S. M., Peer Zada, A. A., Elsässer, A., Kohlmann, A., Haferlach, T., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206664 · Cited by 62
“…by BCR-ABL (Perrotti et al., 2002; Schuster et al., 2003), AML1-ETO (Pabst et al., 2001a), PML-RARa (Truong et al., 2003), and through mutation (Pabst et al., 2001b), thus being a common target in myeloid leukemias, we hypothesized that elevated c-Jun expression in AML might inactivate C/EBPa…”
BackgroundSelf-citationWagner, K., Zhang, P., Rosenbauer, F., Drescher, B., Kobayashi, S., Radomska, H. S., Kutok, J. L., Gilliland, D. G., Krauter, J., & Tenen, D. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508143103 · Cited by 66
Self-citationTavor, S., Park, D. J., Gery, S., Vuong, P. T., Gombart, A. F., & Koeffler, H. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307077200 · Cited by 67
Weisberg, E., Catley, L. P., Kujawa, J., Atadja, P. W., Remiszewski, S., Fuerst, P., Cavazza, C., Anderson, K. C., & Griffin, J. D. (2004) · Leukemia · doi:10.1038/sj.leu.2403519 · Cited by 63
Shim, M., Powers, K. L., Ewing, S. J., Zhu, S., & Smart, R. C. (2005) · PubMed · Cited by 59
The Molecular Pathology of Acute Myeloid Leukemia
Licht, J. D., & Sternberg, D. (2005) · Hematology · doi:10.1182/asheducation-2005.1.137 · Cited by 59
Martinez, N., Drescher, B., Riehle, H., Claire, C., Vornlocher, H., Ganser, A., Heil, G., Nordheim, A., Krauter, J., & Heidenreich, O. T. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-44 · Cited by 64
Schneider, F., Hoster, E., Unterhalt, M., Schneider, S., Dufour, A. M., Benthaus, T., Mellert, G., Zellmeier, E., Bohlander, S. K., Feuring‐Buske, M., et al. (2009) · Blood · doi:10.1182/blood-2008-09-172668 · Cited by 58
Self-citationInfrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia
Chim, C. S., Wong, A. S. Y., & Kwong, Y. L. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03952.x · Cited by 57
“The transcription repression might be mediated through inhibition of the positive autoregulation of the CEBPA promoter by C/EBPa (Pabst et al, 2001b).”
BackgroundHiga, K. C., Goodspeed, A., Chavez, J. S., De Dominici, M., Danis, E., Zaberezhnyy, V., Rabe, J. L., Tenen, D. G., Pietras, E. M., & DeGregori, J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200560 · Cited by 57
“Its function is frequently altered in MDS/MPN and AML by loss-offunction (LOF) mutations or by (epi)genetic alterations that suppress CEBPA expression, such as mutations in NPM1 or RUNX1, FLT3-ITD, AML1-ETO, or BCR-ABL, together accounting for ∼70% of molecular alterations in de novo AML (Ernst et al., 2010; Gu et al.…”
BackgroundSelf-citationSchwieger, M., Löhler, J., Fischer, M., Herwig, U., Tenen, D. G., & Stocking, C. (2003) · Blood · doi:10.1182/blood-2003-07-2280 · Cited by 64
Self-citationMutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7
Langabeer, S. E., Gale, R. E., Rollinson, S. J., Morgan, G. J., & Linch, D. C. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10031 · Cited by 57
“E-mail: stephenl@icr.ac.uk Received 18 June 2001; Accepted 18 September 2001 Published online 1 February 2002 GENES, CHROMOSOMES & CANCER 34:24–32 (2002) DOI 10.1002/gcc.10031 © 2002 Wiley-Liss, Inc. diated through its association with and downregulation of C/EBP (Pabst et al., 2001b).”
BackgroundInfluentialKhanna‐Gupta, A., Zibello, T., Sun, H., Gaines, P. C. W., & Berliner, N. (2003) · Blood · doi:10.1182/blood-2002-09-2767 · Cited by 64
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach
Haferlach, T., Bacher, U., Kern, W., Schnittger, S., & Haferlach, C. (2007) · Annals of Hematology · doi:10.1007/s00277-007-0253-2 · Cited by 62
“AML1 and CEPBA mutations involve genes that code for transcription factors [14, 103, 116].”
Self-citationLin, S., Mulloy, J. C., & Goyama, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_11 · Cited by 60
Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells
Nimer, S. D., & Moore, M. A. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207673 · Cited by 64
“Interference with transcription factors that regulate HSC differentiation or self-renewal In addition to blocking AML1-dependent transcriptional activation, AML1-ETO can also block the Oncogene activating effects of C/EBPa (a bZIP protein), ETS proteins such as PU.1 or MEF, and the Smad proteins involved in the TGFb r…”
BackgroundInfluentialFucikova, J. P., Kašíková, L., Truxová, I., Laco, J., Škapa, P., Ryška, A., & Špíšek, R. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.11.006 · Cited by 62
TAF1 plays a critical role in AML1-ETO driven leukemogenesis
Xu, Y., Man, N., Karl, D. L., Martínez, C., Liu, F., Sun, J., Martinez, C., Martín, G. M., Beckedorff, F., Lai, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12735-z · Cited by 68
Puig-Kröger, A., Sánchez-Elsner, T., Ruiz, N., Andreu, E. J., Prosper, F., Jensen, U. B., Gil, J., Erickson, P., Drabkin, H., Groner, Y., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0618 · Cited by 51
Hyde, R. K., Kamikubo, Y., Anderson, S. M., Kirby, M., Alemu, L., Zhao, L., & Liu, P. (2009) · Blood · doi:10.1182/blood-2009-06-227413 · Cited by 53
Tabe, Y., Jin, L., Contractor, R., Gold, D. L., Ruvolo, P. P., Radke, S., Xu, Y., Tsutusmi-Ishii, Y., Miyake, K., Miyake, N., et al. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402139 · Cited by 59
CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
Lin, T.-C., Hou, H.-A., Chou, W.-C., Ou, D., Yu, S., Tien, H., & Lin, L. (2010) · Leukemia · doi:10.1038/leu.2010.222 · Cited by 55
Paz‐Priel, I., Cai, D. H., Wang, D., Kowalski, J., Blackford, A. L., Liu, H., Heckman, C. A., Gombart, A. F., Koeffler, H. P., Boxer, L. M., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0111 · Cited by 55
“ETO binds and represses the CEBPA promoter, flt3ITD signaling reduces CEBPA mRNA expression, and Bcr-Abl inhibits CEBPA translation (13-15).”
Moore, M. A. S., Dorn, D. C., Schuringa, J. J., Chung, K. Y., & Morrone, G. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.01.018 · Cited by 53
Elagib, K. E., & Goldfarb, A. N. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.010 · Cited by 66
Trivedi, A. K., Bararia, D., Christopeit, M., Zada, A. A. P., Singh, S. M., Kieser, A., Hiddemann, W., Behre, H. M., & Behre, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209964 · Cited by 58
“Potential antagonistic protein interactions leading to a block in C/EBPa function in AML have been well implicated in recent findings (Pabst et al., 2001a; Vangala et al., 2003; Zheng et al., 2004).”
InfluentialSelf-citationCheng, C. K., Li, L., Cheng, S. H., Lau, K., Chan, N. P. H., Wong, R. S. M., Shing, M. M. K., Li, C. K., & Ng, M. H. L. (2008) · Blood · doi:10.1182/blood-2008-02-137083 · Cited by 52
Haefliger, S., Klebig, C., Schaubitzer, K., Schardt, J., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2011) · Blood · doi:10.1182/blood-2010-08-304485 · Cited by 60
Self-citationShim, M., & Smart, R. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301356200 · Cited by 56
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
Rejeski, K., Duque‐Afonso, J., & Lübbert, M. (2021) · Oncogene · doi:10.1038/s41388-021-01952-w · Cited by 60
Koschmieder, S., D'Alò, F., Radomska, H., Schöneich, C., Chang, J. S., Konopleva, M., Kobayashi, S., Levantini, E., Suh, N., Di Ruscio, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-058941 · Cited by 50
Self-citationWierenga, A. T. J., Schepers, H., Moore, M. A. S., Vellenga, E., & Schuringa, J. J. (2006) · Blood · doi:10.1182/blood-2005-11-4608 · Cited by 55
Chou, F., Griesinger, A. M., Wunderlich, M., Lin, S., Link, K. A., Shrestha, M., Goyama, S., Mizukawa, B. E., Shen, S., Marcucci, G., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403212 · Cited by 57
Duque‐Afonso, J., Yalcin, A., Berg, T., Abdelkarim, M., Heidenreich, O. T., & Lübbert, M. (2011) · Oncogene · doi:10.1038/onc.2011.32 · Cited by 52
Role of the COP1 protein in cancer development and therapy
Song, Y., Liu, Y., Pan, S., Xie, S., Wang, Z. P., & Zhu, X. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.001 · Cited by 48
The “Janus” Role of C/EBPs Family Members in Cancer Progression
Tolomeo, M., & Grimaudo, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124308 · Cited by 56
Tonks, A. J., Tonks, A. J., Pearn, L., Pearce, L., Hoy, T. G., Couzens, S., Fisher, J., Burnett, A. K., & Darley, R. L. (2004) · Leukemia · doi:10.1038/sj.leu.2403396 · Cited by 58
Transcriptional mechanisms regulating myeloid-specific genes
Skalnik, D. G. (2002) · Gene · doi:10.1016/s0378-1119(02)00387-6 · Cited by 58
Targeting transcription factors in acute myeloid leukemia
Takei, H., & Kobayashi, S. S. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2488-1 · Cited by 53
Shim, M., Powers, K. L., Ewing, S. J., Zhu, S., & Smart, R. C. (2005) · Cancer Research · doi:10.1158/0008-5472.861.65.3 · Cited by 61
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia
Griffiths, E. A., Gore, S. D., Hooker, C. M., Mohammad, H. P., McDevitt, M. A., Smith, B. D., Karp, J. E., Herman, J. G., & Carraway, H. E. (2010) · Epigenetics · doi:10.4161/epi.5.7.12558 · Cited by 47
Identification of AML1-ETO modulators by chemical genomics
Corsello, S. M., Roti, G., Ross, K. N., Chow, K. T., Galinsky, I. A., DeAngelo, D. J., Stone, R. M., Kung, A. L., Golub, T. R., & Stegmaier, K. (2009) · Blood · doi:10.1182/blood-2008-07-166090 · Cited by 50
Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
Seipel, K., Marques, M. T., Bozzini, M.-A., Meinken, C., Mueller, B. U., & Pabst, T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1054 · Cited by 49
“3_KLF4 (16), pcDNA_TP53, or pcDNA-AML1-ETO (17) expression plasmids (2.”
BackgroundSelf-citationImpaired myelopoiesis in mice devoid of interferon regulatory factor 1
Testa, U., Stellacci, E., Pelosi, E., Sestili, P., Venditti, M., Orsatti, R., Fragale, A., Petrucci, E., Pasquini, L., Belardelli, F., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403472 · Cited by 55
Rücker, F. G., Sander, S., Döhner, K., Döhner, H., Pollack, J. R., & Bullinger, L. (2006) · Leukemia · doi:10.1038/sj.leu.2404235 · Cited by 45
Schepers, H., Wierenga, A. T. J., van Gosliga, D., Eggen, B. J. L., Vellenga, E., & Schuringa, J. J. (2007) · Blood · doi:10.1182/blood-2006-10-052175 · Cited by 53
Klaus, M., Haferlach, T., Schnittger, S., Kern, W., Hiddemann, W., & Schoch, C. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.03.008 · Cited by 46
“[43] Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G,”
BackgroundSelf-citationAML1 Interconnected Pathways of Leukemogenesis: MOLECULAR BIOLOGY AND GENETICS
Michaud, J., Scott, H. S., & Escher, R. (2003) · Cancer Investigation · doi:10.1081/cnv-120018821 · Cited by 53
“However, AML1–ETO also represses C/EBPa,([84,85]) the presence of which seems to be important for p21 expression.”
BackgroundInfluentialBararia, D., Trivedi, A. K., Zada, A. A. P., Greif, P. A., Mulaw, M. A., Christopeit, M., Hiddemann, W., Bohlander, S. K., & Behre, G. (2008) · Leukemia · doi:10.1038/sj.leu.2405101 · Cited by 47
Self-citationHiramoto, T., Ebihara, Y., Mizoguchi, Y., Nakamura, K., Yamaguchi, K., Ueno, K., Nariai, N., Mochizuki, S., Yamamoto, S., Nagasaki, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217039110 · Cited by 45
“, CCAAT/enhancer-binding protein (C/EBP)-α (20), C/EBP-β (21), C/EBP-e (22), and SPI1 (also known as PU.”
Gozzini, A., Rovida, E., Sbarba, P. D., Galimberti, S., Santini, V., & Galimbert, S. (2003) · PubMed · Cited by 53
Schuster, C., Forster, K., Dierks, H., Elsässer, A., Behre, G., Simon, N., Danhauser-Riedl, S., Hallek, M., & Warmuth, M. (2003) · Blood · doi:10.1182/blood-2002-01-0043 · Cited by 43
Self-citationTsiftsoglou, A. S., Bonovolias, I. D., & Tsiftsoglou, S. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.001 · Cited by 50
Wei, Y., Liu, S., Lausen, J., Woodrell, C. D., Cho, S., Biris, N., Kobayashi, N., Wei, Y., Yokoyama, S., & Werner, M. H. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1258 · Cited by 47
Fröhling, S., Schlenk, R. F., Krauter, J., Thiede, C., Ehninger, G., Haase, D. T., Harder, L., Kreitmeier, S., Scholl, C., Caligiuri, M. A., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20152 · Cited by 43
“…and in inv(16)/t(16;16)positive AML, CEBPA expression is down-regulated by the RUNX1–CBFA2T1 and the CBFB–MYH11 fusion proteins, respectively (Pabst et al., 2001a; Cilloni et al., 2003); in t(15;17)-positive acute promyelocytic leukemia, CEBPA DNA binding is inhibited by the PML-RARA…”
BackgroundResultInfluentialDaschkey, S., Röttgers, S., Giri, A., Bradtke, J., Teigler‐Schlegel, A., Meister, G., Borkhardt, A., & Landgraf, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056334 · Cited by 46
Disruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation
Wurm, A. A., Zjablovskaja, P., Kardosova, M., Gerloff, D., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Benoukraf, T., Fricke, S., Hilger, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00032-6 · Cited by 40
“Anti-E2F1 antibody (17-10061) was purchased from Millipore.”
Self-citationTranscriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein
Yang, G., Khalaf, W. F., van de Locht, L. T., Jansen, J. H., Gao, M., Thompson, M. A., van der Reijden, B. A., Gutmann, D. H., Delwel, R., Clapp, D. W., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5869-5879.2005 · Cited by 45
Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5
Walter, K., Cockerill, P. N., Barlow, R. E. L., Clarke, D., Hoogenkamp, M., Follows, G., Richards, S. J., Cullen, M. J., Bonifer, C., & Tagoh, H. (2010) · Oncogene · doi:10.1038/onc.2010.56 · Cited by 44
“These factors are downregulated in t(8;21)-positive AML or mutated (Pabst et al., 2001; Mulloy et al., 2005), raising the possibility that besides aberrant activation, also lack of repression may be involved in the activation of CD19 expression.”
BackgroundLasa, A., Carnicer, M. J., Aventin, A. M., Estivill, C., Brunet, S., Sierra, J., & Nomdedeu, J. F. (2004) · Leukemia · doi:10.1038/sj.leu.2403377 · Cited by 40
Issa, H., Swart, L. E., Rasouli, M., Ashtiani, M., Nakjang, S., Jyotsana, N., Schuschel, K., Heuser, M., Blair, H., & Heidenreich, O. T. (2023) · Leukemia · doi:10.1038/s41375-023-01854-8 · Cited by 39
“Multiple studies have demonstrated an essential requirement for RUNX1/ETO to maintain leukaemic proliferation that is driven by a large transcriptional network comprising direct and indirect target genes of this fusion protein [6, 19-22].”
BackgroundLeukemic stem cells activate lineage inappropriate signalling pathways to promote their growth
Kellaway, S. G., Potluri, S., Keane, P., Blair, H. J., Ames, L., Worker, A., Chin, P. S., Ptasinska, A., Derevyanko, P. K., Adamo, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45691-4 · Cited by 42
“8A), similarly, in SKNO-1 targeted with RUNX1::ETO siRNA both VEGFA and KDR are down-regulated 35 .”
Cooper, S., Parke, H. G., & Friedman, A. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126385 · Cited by 46
Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence
Fischer, M. A., Moreno–Miralles, I., Hunt, A. A., Chyla, B., & Hiebert, S. W. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.500 · Cited by 43
“These fusion proteins have the capacity to repress genes containing a RUNX1 DNA binding site such as p14 ARF ( Cdkn2a isoform4 ), Neurofibromatosis-1 ( Nf-1 ), PU.1 ( Spi1 ), and C/EBP a ( Cebpa ) (Pabst et al , 2001; Linggi et al , 2002; Vangala et al , 2003; Yang et al , 2005).”
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia
Schardt, J., Eyholzer, M., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00870.x · Cited by 41
“In AML patients, deregulation of CEBPA function is a common event comprising genomic mutations [8–10], transcriptional suppression [11] and functional inactivation [12, 13].”
BackgroundSelf-citationBrioschi, M., Fischer, J. A., Cairoli, R., Rossetti, S., Pezzetti, L., Nichelatti, M., Turrini, M., Corlazzoli, F., Scarpati, B., Morra, E., et al. (2010) · Neoplasia · doi:10.1593/neo.10482 · Cited by 41
Marchwicka, A., & Marcinkowska, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071918 · Cited by 41
Gerritsen, M., Yi, G., Tijchon, E. J. H., Kuster, J., Schuringa, J. J., Martens, J. H. A., & Vellenga, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024422 · Cited by 41
“The differentiation block at the GMP stage is linked to a reduced expression of CEBPA in the myeloid lineage, which has been described as a main deregulated gene in AML1-ETO.30 In our study, re-expression of CEBPA partially rescued the differentiation block, which is also in line with findings in AML1-ETO AMLs.31 RNA-…”
Result
Metadata
- Authors
- Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Helmholtz Munich (DE)
- Scripps Research Institute (US)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Medicine
- Published
- 2001-04
- Volume
- 7
- Issue
- 4
- Pages
- 444-451
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1489323849
- Semantic Scholar
- 0dc02b7bfde7f6d2b964fdb5715593ac0bec54f2
- Cited by
- 463
- References
- 45
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 4 · 2021: 16 · 2020: 8 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 18 · 2012: 18
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- AML1-ETO, C/EBPα, CEBPA, acute myeloid leukemia, granulocytic differentiation, transcriptional repression, conditional gene expression, U937 cells, Kasumi-1 cells, therapeutic target
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Animals, Base Sequence, Cell Differentiation, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, DNA-Binding Proteins, Humans, Promoter Regions, Genetic, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Down-Regulation, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.